MedTrace Logo

Dapagliflozin in Patients With Critical Illness

NCT05558098 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 507

Last updated 2023-10-31

No results posted yet for this study

Summary

To assess the effects of dapagliflozin on a composite hierarchical endpoint in critically ill patients.

Conditions

Interventions

DRUG

Dapagliflozin 10mg Tab

Dapagliflozin 10 mg once per day for 14 days or until intensive care unit discharge or death

OTHER

Standard of Care

Current standard of care for management of critically ill patients

Sponsors & Collaborators

  • Hospital Israelita Albert Einstein

    lead OTHER

Principal Investigators

  • Otavio Berwanger, PhD · Academic Research Organization

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-01
Primary Completion
2023-10-20
Completion
2023-10-20

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05558098 on ClinicalTrials.gov